Pharma and BioTech Daily
Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what’s important in pharma and biotech.
Each weekday we condense key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences.
Produced by OWITH.ai, a boutique AI & data studio.
Sponsor the show: https://sponsor.owith.ai
Pharma and BioTech Daily
Latest Episodes
J&J buys Ollin for $2.2B, FDA approves Roche's giredestrant | Pharma and Biotech Daily
Johnson & Johnson pays $2.2 billion upfront for Ollin Biosciences and its Vabysmo challenger OLN324, and the FDA approves Genentech's Wilserdly (giredestrant) for ESR1 mutated breast cancer. Also: Helus Pharma's Phase 3 depression win, Lilly's pur...
FDA rejects Summit's ivonescimab, EU backs AstraZeneca Baxfendy | Pharma and Biotech Daily
The FDA has rejected Summit and Akeso's lung cancer antibody ivonescimab over a missing overall survival win, while Europe's CHMP backed AstraZeneca's blood pressure drug Baxfendy and two China origin lung cancer medicines. We also cover Zevra's u...
Pfizer Blackstone 1.5B obesity deal, FDA vouchers shelved | Pharma and Biotech Daily
Blackstone commits up to 1.5 billion dollars to Pfizer's monthly obesity shot berobenatide, and Reuters reports the FDA has shelved its Commissioner's National Priority Voucher program. Also: FDA staffing gaps, a Bristol Myers Squibb R&D overhaul,...
FDA GLP-1 Vision Warning, Compass Psilocybin NDA | Pharma and Biotech Daily
The FDA adds a possible NAION vision loss risk to the labels of all GLP-1 drugs, and Compass Pathways completes its psilocybin application for treatment resistant depression. Plus AstraZeneca buys Omniose, Abeona licenses a Phase three ready esoph...
Beam Base Editing Sickle Cell Win, FDA Approves Pimjetmi | Pharma and Biotech Daily
Beam Therapeutics' base editing therapy risto-cel meets its primary endpoint in the pivotal BEACON sickle cell study, and the FDA approves Pimjetmi, pimicotinib, from Abbisko and Merck KGaA for tenosynovial giant cell tumor. Also: BIO's BioAdvance...